Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- New trial Spotlight
Multiple solid tumors
Phase 1a/1b BMS-986504 MTA-cooperative PRMT5 inhibitor combo basket in MTAP-deleted tumors.
This Phase 1a/1b, disease-specific basket study tests BMS-986504 (navlimetostat), an MTA-cooperative PRMT5 inhibitor designed to exploit the MTAP-deletion/MTA accumulation vulnerability, in combination with standard…
NCT07532902 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Trastuzumab Deruxtecan (HER2 ADC) posts 50–56% ORR in HER2-mutant mNSCLC
Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody–drug conjugate with a topoisomerase-I payload; in the dose-blinded, randomized Phase 2 DESTINY-Lung02 (NCT04644237), previously treated HER2-mutant mNSCLC…
NCT04644237 - Trial result Spotlight
Acute myeloid leukemia and MDS
CD371/SAVVY/IL-18 Armored CAR T Clears 3/5 r/r AML in First-in-Human Pilot
CD371/SAVVY/IL-18 is a CLEC12A (CD371/CLL-1)–targeted, IL-18–secreting CAR T built with a mutated CD28 costimulatory domain to limit exhaustion; in the Phase I dose-finding study NCT06017258, 5 patients with…
NCT06017258 - Trial result Spotlight
Sarcoma and GIST
Abemaciclib (CDK4/6) + temozolomide/irinotecan delivers durable CR in 5th-relapse ARMS
Abemaciclib is an oral CDK4/6 inhibitor; in JPCS Part A (Phase 1b, NCT04238819) an 8-year-old with 5th-relapse, PAX3-FOXO1, CDK4-amplified ARMS received abemaciclib 55 mg/m² BID continuously with temozolomide 100…
NCT04238819 - New trial Spotlight
Non-small cell lung cancer
Phase II randomized: durvalumab + monalizumab (NKG2A) vs durva + oleclumab (CD73) → RT in PD-L1-high, unresectable stage III
Montefiore compares two chemo-free “priming” pairs (AstraZeneca and Innate Pharma) prior to risk-adapted radiotherapy in treatment-naïve stage III (PD-L1 ≥50%). PACIFIC established durvalumab after chemoradiation;…
NCT07146230 Exploratory - New trial Spotlight
Prostate cancer
Phase Ib ^177Lu-PSMA-617 + liver-directed therapy for mCRPC with liver mets
UCSF evaluates Novartis’ PSMA-targeted Lu-177 radioligand therapy with site-directed treatment (TACE/ablation/Y-90 TARE) for mCRPC patients who’ve progressed on at least one AR-pathway inhibitor. PSMA RLT is a go-to…
NCT07145177 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase I NSC-CRAd-S-pk7 oncolytic adenovirus ± NAC-amide → then SOC chemoradiation/TTFields
Northwestern assesses repeated intratumoral NSC-CRAd-S-pk7 (± NAC-amide) followed by standard temozolomide-radiation and tumor-treating fields (Novocure) in newly diagnosed grade 3/4 glioma. Despite the Stupp…
NCT06169280 First-in-human - New trial Spotlight
Lymphoma
Phase I MB-CART19.1 (CD19 CAR-T) for CNS lymphoma
MSK identifies the maximum safe dose of on-site–manufactured CD19 CAR-T for primary/secondary CNS lymphoma (incl. DLBCL), using CliniMACS Prodigy (Miltenyi Biomedicine), leukapheresis, conditioning chemo, and…
NCT07137494 Exploratory - New trial Spotlight
Stomach and esophageal cancer
Phase II p-HIPEC with cisplatin + paclitaxel during gastrectomy for high-risk gastric/GEJ
Mayo Clinic evaluates heated intraperitoneal cisplatin/paclitaxel delivered intra-op alongside D2 gastrectomy to cut peritoneal relapse. Even with peri-op FLOT, peritoneal spread is the Achilles’ heel; p-HIPEC aims…
NCT07139951 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1a/1b DB-1317 (ADAM9-directed Topo-I ADC) in advanced solid tumors (GI-leaning)
DualityBio’s first-in-human DB-1317 is Q3W, with accelerated titration/BOIN escalation then expansion in GI-heavy tumors (gastric, CRC, PDAC). GI cancers still depend on chemo with few durable targets; ADAM9…
NCT07141706 First-in-human - New trial Spotlight
Multiple solid tumors
Phase I BL-M05D1 CLDN18.2-directed Topo-I ADC (PDAC, biliary, G/GEJ & others)
SystImmune’s first-in-human study assesses safety/PK/efficacy of BL-M05D1 (IV Q3W) in CLDN18.2-expressing tumors, including PDAC, biliary tract cancer, and gastric/GEJ adenocarcinoma. Builds on CLDN18.2 momentum with…
NCT07021066 First-in-human - Trial result Spotlight
Lymphoma
Haihe’s HH2853 (EZH1/2 dual) achieves 31% ORR, 16-mo mPFS in epithelioid sarcoma
HH2853 is an oral dual EZH1/2 histone-methyltransferase (PRC2) inhibitor; in an open-label, global Phase I dose-escalation/expansion (NCT04390737) across refractory solid tumors and NHL (n=61; 57 evaluable), seven…
NCT04390737 - New trial Spotlight
Colorectal cancer
Phase 2 Fruquintinib (VEGFR inhibitor) and Tislelizumab (PD-1 mAb) in MRD-Positive Colorectal Cancer
This Phase 2 trial, sponsored by M.D. Anderson, investigates whether fruquintinib—a VEGFR inhibitor small molecule—and tislelizumab, a PD-1–targeting monoclonal antibody, can reduce recurrence in stage II–IV…
NCT07136077 Exploratory - New trial Spotlight
Lymphoma
Phase II Odronextamab bispecific CD20/CD3 antibody for follicular lymphoma
This Phase II study evaluates odronextamab, a CD20/CD3 bispecific monoclonal antibody, as monotherapy for treatment-naïve follicular lymphoma patients. It uses a multi-cycle dosing design with imaging, ECG, and…
NCT07128641 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase I Trial of Lintuzumab-Ac-225, a CD33-targeted alpha emitter in AML
This Phase I study assesses the safety, tolerability, and optimal dosing of combination treatment with lintuzumab-Ac-225 (a CD33-targeted alpha emitter), venetoclax (a BCL-2 inhibitor), and ASTX-727 (a pairing of…
NCT06802523 Exploratory - New trial Spotlight
Multiple myeloma
Phase Ib Talquetamab bispecific targeting GPRC5D/CD3 and Cilta-cel CAR-T (BCMA) in RRMM
This single-arm Phase 1b trial by the Medical College of Wisconsin evaluates the safety and feasibility of using talquetamab—a bispecific antibody targeting GPRC5D and CD3—as bridging therapy during CAR T-cell…
NCT07093554 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase II Trial of LINAC Stereotactic Radiation, Delivering Precise DNA-Damaging Therapy for Brain Metastases
This study evaluates same-day adaptive LINAC-based stereotactic radiation comparing a 0mm versus a 1mm margin in patients with brain metastases from solid tumors. The design randomizes participants to receive…
NCT07132190 Exploratory - New trial Spotlight
Sarcoma and GIST
Phase II nab-Sirolimus trial: nanoparticle albumin-bound mTOR inhibitor for epithelioid hemangioendothelioma.
Investigating nab-Sirolimus in a non-randomized, open-label, single-arm Phase II trial, Sarcoma Alliance for Research through Collaboration assesses the objective response rate by RECIST v1.1 in patients with…
NCT07104331 Exploratory - New trial Spotlight
Multiple solid tumors
Phase I study of AUBE00, an oral KRAS-targeting agent in solid tumors
This first-in-human Phase I study evaluates safety, pharmacokinetics, pharmacodynamics, immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors harboring KRAS…
NCT07030959 First-in-human - Trial result Spotlight
Non-small cell lung cancer
CT-P16 (bevacizumab biosimilar, anti-VEGF) matches reference bevacizumab in nsNSCLC
From a South Korean biopharma company, Celltrion’s CT-P16 is a bevacizumab biosimilar (anti-VEGF-A mAb). In a randomized, double-blind, global, multicenter Phase 3 first-line study for metastatic/recurrent…
NCT03676192 - Trial result Spotlight
Pancreatic cancer
Atorvastatin (HMG-CoA) + chemotherapy shows 70.3% tumor-marker declines in advanced PDAC
Atorvastatin, an HMG-CoA reductase inhibitor (statin), was paired with chemotherapy after a 260-line PDAC organoid biobank tied chemoresistance to cholesterol/glycosylation programs and showed statins could…
NCT06241352 - Trial result Spotlight
Pancreatic cancer
ELI-002 2P (mKRAS amphiphile) links strong T-cell response to longer RFS/OS in PDAC/CRC
ELI-002 2P is a lymph-node–targeted amphiphile vaccine (KRAS G12D/G12R peptides + CpG-7909) tested as monotherapy in MRD-positive patients after locoregional therapy in Phase 1 AMPLIFY-201 (n=25; PDAC=20, CRC=5). At…
- Trial result Spotlight
Brain and CNS tumors
Azeliragon (RAGE) + SRS posts 100% 8-wk per-patient RANO response in brain metastases
Azeliragon is an oral, brain-penetrant inhibitor of the receptor for advanced glycation end-products (RAGE) intended to dampen neuroinflammation/edema and potentially radiosensitize tumors; in the single-center Phase…
NCT05789589 - New trial Spotlight
Breast cancer
Phase 3 patritumab deruxtecan study of HER3-directed ADC in HR+/HER2- breast cancer
This open-label, randomized Phase 3 trial, sponsored by Merck Sharp & Dohme LLC, evaluates whether patritumab deruxtecan—a HER3-directed antibody–drug conjugate delivering a topoisomerase I inhibitor—improves…
NCT07060807 Registrational - New trial Spotlight
Multiple myeloma
Phase 3 Belantamab Mafodotin Trial – BCMA-targeting ADC in Transplant-Ineligible Myeloma
This Phase 3 randomized, open-label trial at GlaxoSmithKline compares belantamab mafodotin (a BCMA-directed antibody-drug conjugate with a tubulin inhibitor payload) plus lenalidomide and dexamethasone versus…
NCT06679101 Registrational - New trial Spotlight
Brain and CNS tumors
Phase 1 CART-EGFR-IL13Rα2 Cells Targeting EGFR and IL13Rα2 in GBM
This open-label study at the University of Pennsylvania examines newly diagnosed glioblastoma patients with EGFR-amplification and MGMT-unmethylation post-radiotherapy. Eligible patients undergo a two-step screening,…
NCT06973096 First-in-human - New trial Spotlight
Pancreatic cancer
Phase 1b Study of ASP2138, a CLDN18.2-directed CD3 Activator Bispecific mAb
Adults with resectable pancreatic ductal adenocarcinoma expressing CLDN18.2 receive neoadjuvant subcutaneous ASP2138 followed by investigator-selected adjuvant chemotherapy (mFOLFIRINOX, gemcitabine/nab-paclitaxel,…
NCT07024615 Exploratory - New trial Spotlight
Small cell lung cancer
Phase 3 trial of tarlatamab, a DLL3/CD3 bispecific antibody, in extensive-stage SCLC.
This Phase 3 open-label, multicenter randomized trial compares tarlatamab plus durvalumab, carboplatin, and etoposide versus standard durvalumab, carboplatin, and etoposide in untreated stage IV extensive-stage…
NCT07005128 Registrational - New trial Spotlight
Stomach and esophageal cancer
Phase 3 Zolbetuximab (CLDN18.2 mAb) trial in advanced gastric/GEJ cancer
This study compares zolbetuximab combined with pembrolizumab and chemotherapy versus placebo in adults with unresectable or metastatic stomach or GEJ adenocarcinoma that are HER2-negative, CLDN18.2-positive, and…
NCT06901531 Registrational - New trial Spotlight
Multiple solid tumors
Phase 1/2 OBI-902 TROP-2 antibody-drug conjugate trial in advanced solid tumors
This trial is designed to evaluate the safety, pharmacokinetics, and clinical activity of OBI-902 as dose-finding monotherapy in a phase 1 setting and at an optimized dose in phase 2 expansion cohorts. It includes…
NCT07124117 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.